John Flesher, MD
Pulmonary Disease · Wichita, KSNPI 1962469957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 34.0% of the total. Reporting peaked in 2019 at $2,244 and has fallen 60.3% since, to $892 in 2025.
Across 401 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$547
- Veran Medical Technologies, Inc.$265
- Mylan Specialty L.p.$260
- Sunovion Pharmaceuticals Inc.$255
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,29097%
- Education$2173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $2,215 |
| GSK | 109 | $1,114 |
| Boehringer Ingelheim | 28 | $547 |
| Veran Medical Technologies, Inc. | 8 | $265 |
| Mylan Specialty L.p. | 25 | $260 |
| Sunovion Pharmaceuticals Inc. | 45 | $255 |
| Sanofi | 9 | $243 |
| Genentech USA, Inc. | 16 | $225 |
| Novartis | 12 | $177 |
| Actelion Pharmaceuticals US, Inc. | 6 | $173 |
| Regeneron Healthcare Solutions, Inc. | 10 | $172 |
| Grifols USA, LLC | 9 | $172 |
| United Therapeutics Corporation | 23 | $131 |
| Amgen(2 entities) | 5 | $75 |
| Johnson & Johnson | 6 | $74 |
| Harmony Biosciences LLC | 4 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Gilead | 3 | $40 |
| Boston Scientific | 3 | $37 |
| Pulmonx Corporation | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $22 |
| BD | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Covidien LP | 1 | $15 |
| Merck | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,507 in reported general payments places this provider in the 70th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 72 | $929,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,046 | $762,949 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 451 | $309,646 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 19 | $223,744 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 205 | $107,092 |
| Dupixent PenDupilumab | 24 | $99,144 |
| Spiriva RespimatTiotropium Bromide | 116 | $67,399 |
| XolairOmalizumab | 13 | $35,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 211 | $29,129 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $27,785 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $26,366 |
| XareltoRivaroxaban | 25 | $23,830 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $20,730 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 36 | $17,914 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $17,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $547 | $1,040,866252 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,114 | $914,7631,373 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,215 | $348,290557 claims |
| Grifols USA, LLCProlastin C | $172 | $223,74419 claims |
| Johnson & JohnsonXarelto | $74 | $23,83025 claims |
| MerckDulera | $13 | $6,63011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.